Glaukos price target lowered to $140 from $175 at Stifel

Stifel lowered the firm’s price target on Glaukos (GKOS) to $140 from $175 and keeps a Buy rating on the shares. The firm surveyed 34 iDose surgeons, whose iDose volume in Q1 came back “disappointing” with procedures flat quarter-over-quarter. Following the survey work, the firm’s optimism for a “robust” Q1 iDose beat comes down, the analyst tells investors.